Bulletin
Investor Alert

New York Markets Open in:

press release

Sept. 29, 2021, 6:30 a.m. EDT

Adagio Therapeutics to Participate in the Guggenheim 2nd Annual Vaccines & Infectious Day Conference

WALTHAM, Mass., Sep 29, 2021 (GLOBE NEWSWIRE via COMTEX) -- WALTHAM, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., /zigman2/quotes/228559245/composite ADGI -1.50% , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that management will participate in a fireside chat during the Guggenheim 2nd Annual Vaccines & Infectious Day Conference on Wednesday, Oct. 6, 2021 at 1:30 p.m. ET.

The live webcast will be available in the investor section of the company's website at investors.adagiotx.com . The webcast will be archived for 60 days following the presentation.

About Adagio TherapeuticsAdagio /zigman2/quotes/228559245/composite ADGI -1.50% is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company's portfolio of antibodies has been optimized using Adimab's industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio's portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com .

Contacts:Media Contact:Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

COMTEX_394230428/2471/2021-09-29T06:30:17

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/228559245/composite
US : U.S.: Nasdaq
$ 2.63
-0.04 -1.50%
Volume: 744,523
May 24, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$292.83 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/228559245/composite
US : U.S.: Nasdaq
$ 2.63
-0.04 -1.50%
Volume: 744,523
May 24, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$292.83 million
Rev. per Employee
N/A
loading...

Partner Center

Link to MarketWatch's Slice.